Transcode Therapeutics, Inc.

For the period ended Apr 6, 2026. Filed Apr 7, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Apr 6, 2026 · Filed Apr 7, 2026

Use the contents to explore the available documents and sections.

RNAZ$1.49-1.3%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

EX-99.1 · About TransCode Therapeutics

About TransCode Therapeutics

**TransCode Therapeutics, Inc.**is a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.